RxDoctor Payments Data

Rosa Bernier, MD

Family Medicine · Panama City, FLNPI 1164462628

Payments from drug & device makers

$678in general payments, 2019–2025

Across 25 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$387
  • AstraZeneca$106
  • Indivior Inc.$49
  • AbbVie$45
  • Lilly USA, LLC$30
  • Exact Sciences$26
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead7$387
AstraZeneca7$106
Indivior Inc.2$49
AbbVie3$45
Lilly USA, LLC2$30
Exact Sciences2$26
Dexcom, Inc.1$20
Merck1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$678 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$519
Medicare patients
14
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate31$30,701
OzempicSemaglutide19$18,969
LinzessLinaclotide25$15,830
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,195
TrulicityDulaglutide12$11,848
FarxigaDapagliflozin Propanediol11$10,634
Spiriva HandihalerTiotropium Bromide13$10,383
SymbicortBudesonide/Formoterol Fumarate41$9,719
TradjentaLinagliptin19$9,339
RestasisCyclosporine11$7,930
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$6,236
Albuterol Sulfate HfaAlbuterol Sulfate163$5,681
Rosuvastatin Calcium164$3,290
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,504
Risperidone12$2,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$15$30,70131 claims
AbbVieLinzess, Restasis$45$23,76036 claims
AstraZenecaFarxiga, Symbicort$106$20,35352 claims
Lilly USA, LLCTrulicity$30$11,84812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →